This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Knut E. A. Lundin, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT02073526
First received: January 9, 2014
Last updated: December 5, 2016
Last verified: December 2016
  Purpose
Drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-TNF agents. The purpose is to determine which patients that will clinically benefit from either discontinue treatment, adjusting the dose, switch to another anti-TNF agent or a different class of medication.

Condition Intervention
Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis Drug: Infliximab, adalimumab, certolizumab pegol

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

Resource links provided by NLM:


Further study details as provided by Knut E. A. Lundin, Oslo University Hospital:

Primary Outcome Measures:
  • Measurement of drug serum concentrations [ Time Frame: Serum samples will be collected on average 8 weeks (range 0-90 days) after drug administration ]
    Drug serum concentration will be measured using an ELISA


Secondary Outcome Measures:
  • Measure soluble TNF-receptor in serum [ Time Frame: Measurement will be conducted in 2015 on blood samples stored in a bio-bank ]
  • Assay validation [ Time Frame: December 2013 - March 2014 ]
    Drug concentration measurements will be conducted with ELISA's with monoclonal and polyclonal antibodies, automated immunofluorometric assay and commercial kits for the purpose to validate tests and establish standards for measurements

  • Change in individuals drug serum concentration [ Time Frame: Serum samples will be collected on average 8 weeks (range 0-90 days) after drug administration ]
    Intra-individual fluctuations in consecutively measurements during a course of treatment will be measured.


Biospecimen Retention:   Samples With DNA
Serum, whole blood

Enrollment: 1230
Study Start Date: May 2013
Study Completion Date: November 2016
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Anti-TNF
Inflammatory bowel patients age 18 and over treated with anti-TNF agents
Drug: Infliximab, adalimumab, certolizumab pegol
Patients are treated with the above mentioned drugs decided by clinicians

Detailed Description:
Crohn´s disease and ulcerative colitis are diseases where the proinflammatory cytokine Tumor Necrosis Factor-alpha (TNF) plays an important role. Anti-TNF agents are used in the treatment. However, some patients do not respond and response rates declines over time. The cause may be immunogenicity against the agent itself, the agent´s failure to neutralize TNF or another biological pathway leading to inflammation. Anti-TNF agents have been administrated as fixed doses at certain frequencies and this may not be optimal for all patients, but recent studies have indicated a correlation between efficacy and serum drug concentration levels (trough levels). Our preliminary data suggest that trough levels early in the treatment course may be predictive of later trough levels. By multiple measurements, this will be assessed. The study will also investigate biological markers in serum and blood cells which may be predictable for trough levels. Finally, we will compare different methods to measure serum drug concentrations.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Inflammatory bowel disease treated with anti-TNF drug
Criteria

Inclusion Criteria:

  • Patients diagnosed with Inflammatory bowel disease
  • Treated with anti-TNF drug
  • Follow-up at specialized gastroenterologist in Norway
  • Age 18 or over

Exclusion Criteria:

  • Patients refusing to participate by not giving their informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02073526

Locations
Norway
Rikshospitalet-Radiumhospitalet HF, Oslo University Hospital
Oslo, Postboks PB 4950 Nydalen, Norway, 0424
Sponsors and Collaborators
Oslo University Hospital
Investigators
Principal Investigator: Knut EA Lundin, Prof. Oslo University Hospital
  More Information

Responsible Party: Knut E. A. Lundin, Professor, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT02073526     History of Changes
Other Study ID Numbers: 2013-1352
Study First Received: January 9, 2014
Last Updated: December 5, 2016

Keywords provided by Knut E. A. Lundin, Oslo University Hospital:
Antibodies, Monoclonal
Anti-TNF
TNF-alpha
Trough level
Drug concentration
ELISA

Additional relevant MeSH terms:
Crohn Disease
Colitis, Ulcerative
Intestinal Diseases
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colitis
Colonic Diseases
Adalimumab
Infliximab
Certolizumab Pegol
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents
Gastrointestinal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 17, 2017